Loading
Pragmatic trials want to use the progression dates recorded in ordinary clinic notes instead of expensive protocol scans. Checking how well those routine records match formal trial measurements would show when that shortcut is safe.
Paired studies in which patients enrolled in conventional trials also have their routine clinical progression (rwPFS from clinician notes and imaging reports, abstracted or NLP-derived) captured, quantifying agreement in progression dates and hazard ratios by tumour type. Regulators publish acceptable-use conditions for rwPFS and time-to-next-treatment as endpoints in pragmatic and registry-based trials.
Shares Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13, AACR Project GENIE, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Real-world evidence.
Shares RECIST, Real-world evidence, Weak real-world evidence and registries, Progression-free survival (PFS).
Shares Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13, RECIST, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Progression-free survival (PFS).
Shares Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Real-world evidence, Weak real-world evidence and registries, Trial design, endpoints and cost.
Shares Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13, Progression-free survival (PFS), Trial design, endpoints and cost.
Shares Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Real-world evidence, Weak real-world evidence and registries, Trial design, endpoints and cost.
Shares Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13, Progression-free survival (PFS), Trial design, endpoints and cost.
Shares RECIST, Progression-free survival (PFS), Biomarkers are not validated or standardised, Trial design, endpoints and cost.